Why the study?
Little data exists on the cardio-oncological management of cancer patients at high and very-high cardiovascular risk with prior cardiovascular diseases, such as HFrEF or recent myocardial infarction.
How should cancer patients at high and very-high risk of cardiotoxicity, including those with pre-existing cardiovascular diseases, be managed?
How should cancer patients at high and very-high risk of cardiotoxicity, including those with pre-existing cardiovascular diseases, be managed?
This review provides a practical guide for the cardio-oncological management of cancer patients at high and very-high risk of cardiotoxicity, emphasizing multidisciplinary collaboration.
No takes yet. Share an insight, caveat, or question.
Highlights surveillance gaps for lower-risk patients; leaves open optimal monitoring strategies pending prospective data.
Lisi et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: